ALSMA and FR0014005I Related Headlines
Go Back- SMAIO Reported Revenue of €2.8 Million in the First Quarter of 2026, an Increase of 11%
- SMAIO appoints orthopedic surgeon to North American advisory board
- SMAIO Expands Its North American Scientific Advisory Board With a New Renowned Surgeon
- SMAIO Announces that Portzamparc (BNP Paribas Group) has Initiated Coverage of its Stock with a Buy Rating
- SMAIO Reports Strong FY 2025 Results, Amid Robust Growth in Activity
- SMAIO Reports 2025 Sales of €9.2m, Representing an Increase of +67%
- SMAIO: 2026 Financial Calendar
- SMAIO Obtains €2.0m in Non-Dilutive Financing
- SMAIO Successfully Continues Its Think Tanks Focused on Promoting Its Innovative Solutions in the United States
- SMAIO appoints Matthieu Ville as chief commercial officer
- SMAIO Appoints Matthieu Ville as Chief Commercial Officer to Accelerate Commercialization and Strengthen Its Leadership in Spinal Realignment
- SMAIO appoints spine surgeon to US scientific advisory board
- SMAIO Adds a New High-Profile Member to Its Scientific Advisory Board in the United States
- SMAIO Signs a New Distribution Agreement for Its Open Platform KEOPS-4ME With Orthofix in the U.S.
- SMAIO Announces Strong First-Half 2025 Results and Robust Growth in Business Activity in the Third Quarter of 2025
- SMAIO Signs the First Major Distribution Agreement for Its Open Platform KEOPS-4ME with Highridge Medical in the U.S.
- SMAIO Announces Significant Sales Increase in H1 2025
ALSMA and FR0014005I Related Press Releases
Go Back- SMAIO Reported Revenue of €2.8 Million in the First Quarter of 2026, an Increase of 11%
- SMAIO Expands Its North American Scientific Advisory Board With a New Renowned Surgeon
- SMAIO Announces that Portzamparc (BNP Paribas Group) has Initiated Coverage of its Stock with a Buy Rating
- SMAIO Reports Strong FY 2025 Results, Amid Robust Growth in Activity
- SMAIO Reports 2025 Sales of €9.2m, Representing an Increase of +67%
- SMAIO: 2026 Financial Calendar
- SMAIO Obtains €2.0m in Non-Dilutive Financing
- SMAIO Successfully Continues Its Think Tanks Focused on Promoting Its Innovative Solutions in the United States
- SMAIO Appoints Matthieu Ville as Chief Commercial Officer to Accelerate Commercialization and Strengthen Its Leadership in Spinal Realignment
- SMAIO Adds a New High-Profile Member to Its Scientific Advisory Board in the United States
- SMAIO Signs a New Distribution Agreement for Its Open Platform KEOPS-4ME With Orthofix in the U.S.
- SMAIO Announces Strong First-Half 2025 Results and Robust Growth in Business Activity in the Third Quarter of 2025
- SMAIO Signs the First Major Distribution Agreement for Its Open Platform KEOPS-4ME with Highridge Medical in the U.S.
- SMAIO Announces Significant Sales Increase in H1 2025
